转化生物医学

  • 国际标准期刊号: 2172-0479
  • 期刊 h 指数: 16
  • 期刊引用分数: 5.91
  • 期刊影响因子: 3.66
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 研究圣经
  • 全球影响因子 (GIF)
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Needs-driven rather than market-driven rules to spread access to medicines in poor countries

Daniele Dionisio

Back ground: Communicable diseases (including HIV/AIDS, malaria, tuberculosis, schistosomiasis, river blindness, Chagas,sleeping sickness, and leishmaniasis) disproportionately affect the people living in resource-limited countries.While current patent system does not work for poor end users in these countries, it adds to the stranglehold on accessto lifesaving medicines by the protectionist policies of wealthy countries. Nonetheless, increasing pressure is registerednowadays for strategies up to promoting pharmaceutical innovation, research and development (R&D) and equitableaccess to medicines in the sake of the worst-off.

Method: Analysis here will compare some strategy models in theirpotential to fairly attune patents to innovation, R&D and access, in the light of new perspectives by governments andinstitutions aligning with the spirit and resolutions of just closed sixty-third WHO World Health Assembly.

Conclusion: No single model is likely to be enough solution, and a combination of two or more may be needed to ensure thatoutputs of R&D, innovation and access are available without restrictions. To this aim, all models should complementcurrent intellectual property regimens and channel open source schemes, sustainable financing mechanisms, andneeds-driven rather than merely market-driven rules.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证